Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,921 to 1,940 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid. | Cytotherapy | 2021 | 34312069 | PubTator, text mining | PubMed |
| Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma. | Front Mol Biosci | 2021 | 34307451 | PubTator, text mining | PubMed |
| Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities. | Front Cell Dev Biol | 2021 | 34307352 | PubTator, text mining | PubMed |
| Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. | Pharmacol Res | 2021 | 34302977 | PubTator, text mining | PubMed |
| Advances in Immunotherapy for Adult Glioblastoma. | Cancers (Basel) | 2021 | 34298615 | PubTator, text mining | PubMed |
| Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?-a narrative review. | Transl Lung Cancer Res | 2021 | 34295669 | PubTator, text mining | PubMed |
| A Novel Ferroptosis-Related Biomarker Signature to Predict Overall Survival of Esophageal Squamous Cell Carcinoma. | Front Mol Biosci | 2021 | 34291083 | PubTator, text mining | PubMed |
| Peripheral blood transcriptome heterogeneity and prognostic potential in lung cancer revealed by RNA-Seq. | J Cell Mol Med | 2021 | 34288383 | PubTator, text mining | PubMed |
| Antioxidant Supplements versus Health Benefits of Brief/Intermittent Exposure to Potentially Toxic Physical or Chemical Agents. | Curr Issues Mol Biol | 2021 | 34287292 | PubTator, text mining | PubMed |
| Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma. | Neurooncol Adv | 2021 | 34286278 | PubTator, text mining | PubMed |
| Molecular Update and Evolving Classification of Large B-Cell Lymphoma. | Cancers (Basel) | 2021 | 34283060 | PubTator, text mining | PubMed |
| METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis. | Cancer Cell Int | 2021 | 34281539 | PubTator, text mining | PubMed |
| Epstein-Barr Virus Induced Cytidine Metabolism Roles in Transformed B-Cell Growth and Survival. | mBio | 2021 | 34281398 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors in lymphoma: challenges and opportunities. | Ann Transl Med | 2021 | 34277837 | PubTator, text mining | PubMed |
| The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. | BMC Cancer | 2021 | 34275438 | PubTator, text mining | PubMed |
| The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma. | Ann Transl Med | 2021 | 34268412 | PubTator, text mining | PubMed |
| Co-stimulatory agonists: An insight into the immunotherapy of cancer. | EXCLI J | 2021 | 34267616 | PubTator, text mining | PubMed |
| Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. | Blood Cancer J | 2021 | 34267187 | PubTator, text mining | PubMed |
| Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. | Blood Cancer J | 2021 | 34267181 | PubTator, text mining | PubMed |
| Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications. | Front Cell Dev Biol | 2021 | 34262904 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=97